A case of autoimmune myositis after treatment with alemtuzumab for multiple sclerosis
نویسندگان
چکیده
منابع مشابه
Graves' disease after treatment with alemtuzumab for multiple sclerosis.
CONTEXT Alemtuzumab, a humanized monoclonal antibody against CD52, is effective in the treatment of early relapsing-remitting multiple sclerosis (MS). Common adverse effects include an acute-phase reaction, infections and autoimmune diseases, including thyroid disorders. SETTING Patients from two phase 3 trials (CARE MS 1 and 2, n=15) were studied in a clinical research center. PATIENTS Fiv...
متن کاملP 53: Stem Cell Therapy for Treatment of Autoimmune Diseases (with Emphasis on Multiple Sclerosis)
Autoimmune diseases have been described as an interesting and poorly understood group of disorders. There are many challenges in the respective scientific societies concerning the nature, causes and the therapeutic approaches of these diseases. In accordance with the evidences the nature and etiology of these disorders is multifactorial and complex but the clearest definition could be expressed...
متن کاملAlemtuzumab for the treatment of multiple sclerosis
INTRODUCTION Alemtuzumab is a monoclonal antibody that targets for the destruction CD52+ cells, particularly B and T cells. Alemtuzumab is approved in more than 50 countries around the world for the treatment of adult patients with relapsing remitting multiple sclerosis (MS). Areas covered: In this review, the authors summarize biological, clinical and safety data related to the use of alemtuzu...
متن کاملPredicting autoimmunity after alemtuzumab treatment of multiple sclerosis.
OBJECTIVE We have previously shown that autoimmunity following alemtuzumab treatment of multiple sclerosis can be predicted by high baseline serum interleukin IL-21 (IL-21), as measured using a now 'redundant' enzyme linked immunosorbent assay (ELISA). Here we ask whether currently available ELISAs have similar prognostic value. DESIGN Serum IL-21 from 141 individuals with relapsing remitting...
متن کاملImmune competence after alemtuzumab treatment of multiple sclerosis.
OBJECTIVE To determine the immunocompetency of patients with multiple sclerosis treated with the lymphodepleting humanized monoclonal antibody alemtuzumab. METHODS In this pilot case-control study, we assessed immunocompetence in 24 patients after alemtuzumab treatment by measuring antibody responses to 3 vaccines (diphtheria, tetanus, and poliomyelitis vaccine, Haemophilus influenzae type b ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Multiple Sclerosis Journal - Experimental, Translational and Clinical
سال: 2018
ISSN: 2055-2173,2055-2173
DOI: 10.1177/2055217318819012